That RNS feels like it skirts over the broad implications of this news, implications that could be stated right here and right now, whatever the detail of the way forward will look like. It feels a bit slimy and evasive, in other words. |
Lost £500 on a bad trade. Given my view of TM, I really should have resisted. Oh well. As for those buying.....market cap still £17m. It should probably be well into the low single figures, so another 50%+ downside to go. |
Did you all expect to multi-bag within a month?
I'm buying your shares on the cheap. Watch and learn. |
As ever precise but vague - experts with a different view and unfortunately the FDA experts hold the key to approval; still if Avion experts thought investment worthwhile and PK study met the objective, whatever that was, then its unclear if the FDA response is a kiss of death or a delaying tactic. Strategical I think the company made a mistake in either:
- not selling rights to a large pharma
- seeking approval out of USA; US is toxic for example LUPUZOR was not US approved but was elsewhere in EU, Japan etc.
So jury is out, its ether still possible to fly or doomed, but as it came out of CNRS, another load of expert, maybe its still a fighting chance. So until we get, if ever, the real detail of FDA points its all foggy. |
Another Tim but dim result. |
I've sold out of IMM on the news as well. Have a tonne of EVG which also in terms of share price has been disappointing. |
Fortunately had none but that RNS is a clear sell in my view. Clarity needed to make any investment case at all. |
Thats not good. Ffs |
I'm out with a loss. McCarthy should be locked up.... |
This RNS should sink IMM share.
Very bad look
Sigh |
What a shocker. It looks like Tim did indeed lie… |
Nobby - Thank you. Fingers crossed!
BS lord - it’s habit of Dogs to bark but I can’t stop them ;)
Hope I will show you the same screenshot for IMM
Enjoy
hxxps://paste.pics/0dced47fee45f15276e51bab32b43421 |
Nobby - thought you might say that and I'm sure you also took other factors into account. But presumably Tim's previous predictions (which all turned out to be wrong) were also either written down or on camera? |
And of course the 80:20 prediction does not only rely on that one statement…R30; |
Well I am assuming not even Tim could utter such a blatant lie on a public broadcast….. |
Nobby - it was interesting to hear what you reckoned the odds were. But concerning you seem to be basing this on reassurances from Tim McDim. Given your frequently expressed contempt for McCarthy, why would his comments suddenly hold sway? |
Eva Perón - you do realise your story gets more implausible by the day? Next you'll be telling us you've taken over Starbucks. |
We have gone over all of this before. The FDA clearly have some concerns about the PK of the drug but McCarthy did say in the meeting in response to a question that the trial had already been approved and they were just doing the belt and braces for the FDA. That is why I give it an 80:20 chance of going ahead as stated in a post last week.
But when it comes to drug trials you can never say never… |
Nobby, why wouldn;t it? FDA would be doing an injustice not to allow to see if it benefits sufferers!!!! |
Should be good timing in terms of news from the FDA which must be due any day now as they are over 2 weeks late. I hope for your sake it’s positive and the trial will go ahead… |
Halfbutt - with todays £12k but
Now I’ve total £255k
Loss of £64k so far
Yes thanks to SNG profit / I bought flat at Hammersmith which is now rented and managed by agent.
Anyway, Catch you later - bit busy
Should IMM give me SNG like profit then plan is to buy another big caffe and j just off to beach |
Added further
Order reference
204101480
Investment name
Immupharma Plc
Investment code
IMM.LN
Date order placed
13/09/2022
Time order placed
12:24:14
Settlement date
16/09/2022
Number of shares or units
181370
Share or unit price
6.60p
Consideration
£11,978.94
Transaction charge
£20.00
PTM Levy
£1.00
Total charges
£21.00 |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
